索马托斯塔丁用于治疗血和 melaena 的治疗
Lancet (London, England)
|January 19, 1985
概括
这项研究发现,体静止素输注并没有显著减少胃肠道出血患者的再出血. 虽然在接受治疗的患者中,再出血的发生较少,但结果与安慰剂相似,质疑早期的益处主张.
科学领域:
- 胃肠病学 胃肠病学
- 临床试验 临床试验
- 药理学 药理学是指药理学的学科.
背景情况:
- 胃肠道出血,其特点是血和 melaena,是一个重要的临床问题.
- 之前的较小的研究表明,索马托斯塔丁在治疗这些疾病方面具有潜在的益处.
研究的目的:
- 评估与安慰剂相比,连续静脉注射索马托斯塔丁输液在患有血和 melaena 的患者中的疗效.
- 评估索马托斯塔丁对再出血率,手术需要和死亡率的影响.
主要方法:
- 这是一项双盲,随机对照试验,涉及630名患有血和梅拉纳的患者.
- 患者被分配给通过持续静脉输液接受索马托斯塔丁或相同的安慰剂.
- 记录和比较了包括再出血事件,手术率和死亡率在内的结果.
主要成果:
- 在315名接受治疗的患者中,有70人出现了复出出血,而在315名对照组中,有89人出现了复出血,这一差异在统计学上并不显著.
- 在体静止素组 (35名患者) 和安慰剂组 (34名患者) 之间,手术发生率相似.
- 与安慰剂组 (25例死亡) 相比,体静止素治疗组 (31例死亡) 的死亡率略高.
结论:
- 这些发现表明,持续静脉注射索马托斯塔丁输液在减少血和 melaena 患者的再出血方面没有显著的益处.
- 这些结果与之前关于显著有效性的报道相矛盾,表明索马托斯塔丁显著益处的说法可能不合理.
- 虽然不能完全排除对特定个体的益处,但总体证据不支持基于这项试验的广泛使用.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
Esophageal Varices-II: Clinical Features and Management
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Gastritis III: Clinical Manifestations and Management
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Peptic Ulcer Disease IV: Management
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...


